Navigation

2006/046 NICE recommends rituximab for the first line treatment of follicular lymphoma

NICE has today issued guidance to the NHS in England in Wales recommending rituximab, within its licensed indications, (that is, in combination with cyclophosphamide, vincristine and prednisolone - or CVP) as an option for the treatment of patients with symptomatic stage III and IV follicular lymphoma who have previously been untreated.

This page was last updated: 05 March 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.